The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

Hepatic steatosis steadily increased in patients with HIV and HCV coinfection despite curative treatment with DAA therapy.

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

Patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis who received a novel ...

Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to ...

Patients in the treatment arms received 1 mg, 2.5 mg, 5 mg or 10 mg doses. After 52 weeks of treatment, patients taking the ...

Carisma Therapeutics Inc. (CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at the ...

Astrazeneca plc has developed a potent oral fibroblast activation protein (FAP) inhibitor, AZD-2389, that avoids the cleavage of FGF21 and α2-AP. AZD-2389 was tested in cynomolgus monkeys with ...

Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three ...